Clarityfor strategy.
Convictionfor investment.
Precisionfor activation.
One curated evidence base.
More context for every decision.
PURPOSE-BUILT FOR OBESITY
Our AI-powered pipeline structures and enriches fragmented data, preserving the source behind each insight.
EXPLORE THE PLATFORM
Four disciplines. One connected view.
Assess competitor assets, clinical evidence and upcoming milestones in one view.
Assess differentiation and sharpen your positioning.
BUILT FOR YOUR DECISIONS
Choose the decision in front of you.
Clinical results and competitor moves can change your position.
Compare assets, evidence and access changes to see which planning assumptions need review.
Clinical promise is only part of the investment case.
Bring competitive evidence, pricing context and analyst outlooks together to test your thesis.
A broad HCP list does not tell you whom to prioritize.
Use clinical interests and professional networks to build more relevant audiences.
Understand competitor moves, pricing shifts, and emerging evidence.
Put your next commercial decision in context.
Clarityfor commercial strategy.
Convictionfor investment.
Precisionfor activation.
A WIDER VIEW. A SHARPER READ.
THE U.S. OBESITY LANDSCAPEA trial result, a pricing change, or a new forecast can affect your plans. MEDAIM brings the relevant evidence together to help you assess the implications.
The developments worth your attention.
How evidence and market behavior connect.
The source and history behind each shift.
01 / CONNECT THE SIGNALS
MEDAIM unifies data across the obesity landscape into a curated evidence base.Our AI-powered data pipeline structures and enriches that evidence, preserving source context for deeper analysis.
CURATED FOR PERSPECTIVE
A price point is only part of the story. MEDAIM connects market movements over time to reveal competitive patterns, shifts in affordability, and the context behind them.
Understand what pricing behavior could mean for your commercial position.
Explore the perspective each discipline brings.
02 / SPECIALIST DEPTH. UNIFIED INTELLIGENCE.
Four connected disciplines.
One dedicated obesity perspective.
Understand obesity drug affordability beyond the headline. Connect current offers, eligibility, presentation, and price history.
Bring obesity assets, clinical evidence, publications, and competitor strategy into a connected market perspective.
Connect HCP intelligence with targeting and segmentation to focus marketing activation on the audiences that matter.
Connect analyst perspectives, product forecasts, and market-share expectations to your obesity commercial strategy.
03 / USE CASES
Apply connected obesity intelligence to the decisions in front of you.
New clinical results, competitor milestones, and access changes can challenge your strategy. Their combined impact is difficult to assess across separate sources.
MEDAIM brings these developments into a shared view of the obesity landscape, helping you assess differentiation and identify which positioning or planning assumptions need review.
An asset’s potential depends on more than its clinical results. Competitive alternatives, affordability, and commercial expectations can strengthen or weaken the investment case.
MEDAIM connects clinical and competitive evidence with pricing context and analyst outlooks, helping you test the thesis and identify uncertainties that warrant deeper diligence.
Broad HCP lists offer limited guidance on whom to prioritize or how to form relevant audiences for a campaign.
MEDAIM combines HCP profiles, clinical interests, and professional networks to support targeting and segmentation, giving marketing teams a clearer basis for activation planning.
04 / PERSPECTIVE
A dedicated intelligence perspective for the
science and commercial dynamics of obesity.
Obesity is our domain. We connect mechanisms, clinical evidence, access models, and competitive dynamics.
Turn fragmented research into structured findings, connecting companies, molecules, trials, and expert perspectives.
Source-linked research and pricing history help you understand what changed and form an informed judgment.
SEE THE SIGNAL. UNDERSTAND THE SHIFT.
Bring specialist obesity intelligence to your next decision.